NRIX
Nurix Therapeutics Inc.
$12.94
+$0.16(+1.25%)
80
Overall
60
Value
100
Tech
--
Quality
Market Cap
$682.69M
Volume
1.68M
52W Range
$8.18 - $29.56
Target Price
$27.78
Order:
Income Statement
| Metric | Trend | Chart | 2020 Nov | 2021 Nov | 2022 Nov | 2023 Nov | 2024 Nov |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | ||
| Total Revenue | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $82.8M | $147.6M | $222.5M | $232.1M | $267.6M | ||
| Research & Development | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | ||
| Research Expense | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | ||
| Selling, General & Administrative | $16.3M | $31.2M | $38.0M | $42.9M | $45.9M | ||
| General & Administrative Expenses | $16.3M | $31.2M | $38.0M | $42.9M | $45.9M | ||
| Depreciation & Amortization | $2.2M | $2.8M | $5.3M | $7.5M | $9.3M | ||
| Depreciation & Amortization | $2.2M | $2.8M | -- | -- | -- | ||
| Other Operating Expenses | $-1.3M | $-2.3M | -- | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-65.0M | $-117.9M | $-183.9M | $-155.1M | $-213.0M | ||
| EBITDA | $-62.8M | $-111.8M | $-169.6M | $-130.3M | $-176.9M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $1.2M | $823.0K | $3.5M | $11.1M | $19.7M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $823.0K | $3.5M | $11.1M | $19.7M | ||
| Other Income/Expense | $-15.1M | -- | -- | -- | -- | ||
| Other Special Charges | $15.1M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-65.0M | $-117.9M | $-180.4M | $-143.9M | $-193.3M | ||
| Pre-Tax Income | $-63.8M | $-117.1M | $-180.4M | $-143.9M | $-193.3M | ||
| INCOME TAX | |||||||
| Tax Provision | $-20.5M | $131.0K | -- | -- | $270.0K | ||
| NET INCOME | |||||||
| Net Income | $-43.2M | $-117.2M | $-180.4M | $-143.9M | $-193.6M | ||
| Net Income (Continuing Operations) | $-43.2M | $-117.2M | $-180.4M | $-143.9M | $-193.6M | ||
| Net Income (Discontinued Operations) | $-43.2M | $-117.2M | $-180.4M | $-143.9M | $-193.6M | ||
| Net Income (Common Stockholders) | $-43.2M | $-117.2M | $-180.4M | $-143.9M | $-193.6M | ||
| Normalized Income | -- | $-92.5M | -- | -- | -- | ||
| TOTALS | |||||||
| Total Expenses | $82.8M | $147.6M | $222.5M | $232.1M | $267.6M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $15.7M | $42.9M | $48.6M | $54.3M | $67.1M | ||
| Average Shares Outstanding (Diluted) | $15.7M | -- | $48.6M | $54.3M | $67.1M | ||
| Shares Outstanding | $38.9M | $44.7M | $47.3M | $48.9M | $75.9M | ||
| Basic EPS | $-2.76 | $-2.73 | $-3.71 | $-2.65 | $-2.88 | ||
| Basic EPS (Continuing Operations) | $-2.76 | $-2.73 | $-3.71 | $-2.65 | $-2.88 | ||
| Diluted EPS | $-2.76 | $-2.73 | $-3.71 | $-2.65 | $-2.88 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.71 | $-2.65 | $-2.88 | ||
| OTHER METRICS | |||||||
| Other Gand A | $16.3M | $31.2M | $38.0M | $42.9M | $45.9M | ||
| Rent And Landing Fees | $3.0M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NRIX | $12.94 | +1.3% | 1.68M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |